Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?

Tumor-infiltrating T lymphocytes (TILs) are observed in a number of human primary or metastatic tumors. Recently, gene expression profiling experiments suggested that the presence of T cells in metastatic melanomas before vaccinating the patients with tumor antigens could be a biomarker for clinical...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Immunology, Immunotherapy Vol. 60; no. 8; pp. 1153 - 1160
Main Authors: Cipponi, Arcadi, Wieers, Grégoire, van Baren, Nicolas, Coulie, Pierre G.
Format: Journal Article
Language:English
Published: Berlin/Heidelberg Springer-Verlag 01.08.2011
Springer
Springer Nature B.V
Subjects:
Animals
Antigens
Antigens, Neoplasm - immunology
Antineoplastic agents
Biological and medical sciences
Biomarkers
Biomarkers, Pharmacological - metabolism
Biopsy
Cancer
Cancer Research
Cancer Vaccines
Dermatology
Focussed Research Review
Gene expression
Gene Expression Profiling
Humans
Immunization
Immunology
Immunotherapy
Lymphatic system
Lymphocytes
Lymphocytes, Tumor-Infiltrating - immunology
Medical prognosis
Medical research
Medical sciences
Medicine
Medicine & Public Health
Melanoma
Melanoma - diagnosis
Melanoma - immunology
Melanoma - pathology
Metastasis
Multivariate analysis
Neoplasm Metastasis
Oncology
Patient Selection
Patients
Pharmacology. Drug treatments
Prognosis
Skin Neoplasms - diagnosis
Skin Neoplasms - immunology
Skin Neoplasms - pathology
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
Vaccines
Belgium
PIVAC 10
Prognosis
T lymphocyte
Immunotherapy
Melanoma
Human
Patient
Tumor infiltrating lymphocyte
Malignant tumor
Treatment
T-Lymphocyte
Malignant melanoma
Cancer
ISSN:0340-7004, 1432-0851, 1432-0851
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor-infiltrating T lymphocytes (TILs) are observed in a number of human primary or metastatic tumors. Recently, gene expression profiling experiments suggested that the presence of T cells in metastatic melanomas before vaccinating the patients with tumor antigens could be a biomarker for clinical benefit from the vaccines. In this context, we review results pertaining to TILs in human melanomas, their prognostic value, and some possible reasons why their presence could help in selecting melanoma patients for vaccination against tumor-specific antigens.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0340-7004
1432-0851
1432-0851
DOI:10.1007/s00262-011-1026-2